Dark Matter Blog

APRIL 4, 2023

Prior to 2015, I had a casual relationship, at best, with targeting RNA. Targeting RNA is a Whole New World Then in 2015, I became smitten and eloped with RNA, setting out to build a company devoted to bringing to bear industrial drug discovery concepts and methods on a new problem of drugging RNA with small molecules.

Small Molecule 52

Small Molecule RNA Fragment Screening DNA 52

Sygnature Discovery

SEPTEMBER 12, 2024

Structures solved of many different protein classes, including membrane proteins, protein complexes and recently RNA. With capabilities across X-ray Crystallography Crystallisation/co-crystallisation screening of proteins, DNA, and RNA using in-house and commercial screens at various temperature.

Fragment Screening 52

Fragment Screening RNA Protein Production DNA 52

Sygnature Discovery

JUNE 17, 2024

Diverse Target Classes We Work With: Soluble Proteins: This includes kinases, ligases, transcription factors, helicases, polymerases, and DNA/RNA modifying enzymes, among others. Membrane Proteins: Examples include cell surface receptors, GPCRs, and transporters. Nucleic Acid Targets: Focusing on specific interactions and functions.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Sygnature Discovery

JUNE 17, 2024

MST is less restricted by molecular weight and buffer composition in small molecule assays and can analyse interactions with various molecules, including RNA/DNA, lipids, carbohydrates, and proteins, even membrane-bound ones. This technology measures affinities from mM to nM.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52